Pharvaris N.V.
corporate_fare Company Profile
Pharvaris N.V. (NASDAQ:PHVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for PHVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for PHVS spans 144, 6-K, 424B5, 20-F.
Recent high-impact activity:
- Pharvaris Officer/Director Schikan Files to Sell 200,000 Shares Worth $7M
- Pharvaris Insider Schoodic Management BV Files to Sell 300,000 Shares Worth $10.5M
- Pharvaris CHAPTER-3 Data: 83% Attack Reduction, All Secondary Endpoints Met
- Pharvaris' CHAPTER-3 Pivotal Study Meets Primary Endpoint: 83% Attack Rate Reduction
- Pharvaris' CHAPTER-3 Hits Primary Endpoint: 83% Attack Reduction in HAE Prophylaxis
Financial Snapshot
Short Interest & Short Volume
1.24 days to coverFINRA reported short interest of 1,784,789 shares in PHVS as of the September 15, 2026 settlement, a 17.4% decrease from the prior period — about 1.2 days to cover at its recent average daily volume. On October 2, 2026, 43.5% of PHVS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PHVS, detected from its recent SEC filings · based on capital-structure filings through 2026-05-08.
Offering Priced · Capital Raised
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
PHVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.